Comparative Pharmacology
Head-to-head clinical analysis: PIPERAZINE CITRATE versus VERMIDOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PIPERAZINE CITRATE versus VERMIDOL.
PIPERAZINE CITRATE vs VERMIDOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Piperazine citrate acts as a gamma-aminobutyric acid (GABA) receptor agonist in nematodes, causing hyperpolarization of nerve membranes and flaccid paralysis of the worm, which is then expelled by normal peristalsis. It does not affect mammalian neuromuscular junctions due to differences in GABA receptor sensitivity.
VERMIDOL is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, thereby reducing prostaglandin synthesis and attenuating pain, inflammation, and fever.
Adults: 3.5 g orally once daily for 2 days; may repeat after 1 week if needed.
200 mg orally twice daily for 3 days; maximum 400 mg per day.
None Documented
None Documented
Terminal elimination half-life: 2-4 hours in patients with normal renal function; may be prolonged in renal impairment.
Terminal elimination half-life: 8-12 hours (mean 10 h); prolonged in renal impairment (up to 24 h) and elderly.
Primarily renal (60-70% unchanged); biliary/fecal elimination accounts for 10-20% of the dose.
Renal: ~60-70% as unchanged drug; biliary/fecal: ~20-30%; minor metabolism via hepatic CYP3A4.
Category C
Category C
Anthelmintic
Anthelmintic